Basic information of IL22 :
| Official Symbol of Gene | IL22 |
| Species | Homo sapiens |
| Entrez Gene ID | 50616 |
| Official Full Name | interleukin 22 |
| Also known as | TIFa; IL-21; IL-22; ILTIF; IL-TIF; IL-D110; zcyto18; TIFIL-23 |
| Gene Type | protein coding |
| dbXrefs | Ensembl:ENSG00000127318 MIM:605330; AllianceGenome:HGNC:14900 |
| Map Location | 12q15 |
| Variation Type | gene polymorphism |
| refSNP ID | N/A |
Sample information of multiple sclerosis:
| Detected Sample | the serum,the cerebrospinal fluid, and immune cells of peripheral blood |
| Sample Detail | N/A |
| Detected Method | ELISAã€qPCR |
| Disease | MS |
| Disease subtype | N/A |
| Population | N/A |
| Sample Size | 141 MS patients and healthy control |
Literature information of multiple sclerosis :
| Pubmed ID | 26077779 |
| Year | 2015 |
| Title | Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes |
Results of multiple sclerosis :
| Risk Type | Disease risk |
| Main Result | positive |
| Result | We show that (1) there is a dysregulation in the expression of IL-22 and its antagonist, IL-22BP, in MS patients, (2) IL-22 targets specifically astrocytes in the human brain, and (3) this cytokine confers an increased survival of the latter cells. |
| Mechanism/Pathway | tumor necrosis factor 伪-treated astrocytes had a better long-term survival capacity upon IL-22 co-treatment |
